文献速递艾滋病与性传播感染

妊娠期及产后含多替拉韦和富马酸替诺福韦艾拉酚胺抗逆转录病毒治疗方案的体重变化与不良妊娠结局

Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.
PubMed 文献 · Clin Infect Dis · 2024-01-01

在9个国家开展的IMPAACT 2010随机试验纳入643名HIV-1感染孕妇,比较含多替拉韦联合恩曲他滨/富马酸替诺福韦艾拉酚胺、多替拉韦联合恩曲他滨/富马酸替诺福韦二吡呋酯及依非韦伦联合恩曲他滨/富马酸替诺福韦二吡呋酯三种方案。妊娠期体重增长不足与复合不良妊娠结局风险升高相关(HR 1.44),多替拉韦联合富马酸替诺福韦艾拉酚胺组复合不良妊娠结局率最低,但产后50周BMI≥25比例最高(54.7%)。

要点

  • 妊娠期体重增长不足与复合不良妊娠结局风险升高相关(HR 1.44,95%CI 1.04-2.00)。
  • 多替拉韦联合富马酸替诺福韦艾拉酚胺组体重增长不足发生率最低(15.0%),复合不良妊娠结局率也最低。
  • 多替拉韦联合富马酸替诺福韦艾拉酚胺组产后50周BMI≥25比例最高(54.7%),需干预以减少产后体重增加。

核心结论

  • 妊娠期使用含多替拉韦方案的体重增长对通常与体重增长不足相关的不良妊娠结局具有保护作用,支持指南推荐妊娠期启动抗逆转录病毒治疗的女性使用以多替拉韦为基础的方案。
  • 需要采取干预措施以减轻产后体重增加。

研究设计与样本

  • IMPAACT 2010随机试验,纳入9个国家HIV-1感染孕妇,于孕14-28周按1:1:1随机分配至多替拉韦+恩曲他滨/富马酸替诺福韦艾拉酚胺组(217例)、多替拉韦+恩曲他滨/富马酸替诺福韦二吡呋酯组(215例)或依非韦伦+恩曲他滨/富马酸替诺福韦二吡呋酯组(211例),共643例。

主要发现

  • 基线中位孕周21.9周,中位HIV RNA 903拷贝/mL,中位CD4细胞计数466/μL。
  • 妊娠期体重增长不足发生率:多替拉韦+恩曲他滨/富马酸替诺福韦艾拉酚胺组15.0%,多替拉韦+恩曲他滨/富马酸替诺福韦二吡呋酯组23.6%,依非韦伦+恩曲他滨/富马酸替诺福韦二吡呋酯组30.4%。
  • 多替拉韦+恩曲他滨/富马酸替诺福韦艾拉酚胺组复合不良妊娠结局发生率最低。
  • 妊娠期体重增长不足与复合不良妊娠结局风险升高相关(HR 1.44,95%CI 1.04-2.00),与小于胎龄儿风险升高相关(HR 1.48,95%CI 0.99-2.22)。
  • 产后50周BMI≥25的比例:多替拉韦+恩曲他滨/富马酸替诺福韦艾拉酚胺组54.7%,多替拉韦+恩曲他滨/富马酸替诺福韦二吡呋酯组45.2%,依非韦伦+恩曲他滨/富马酸替诺福韦二吡呋酯组34.2%。

关键数值与推荐

  • 妊娠期体重增长不足依据美国医学研究所指南定义。
  • 不良妊娠结局包括死产(≥20周孕周)、早产(<37周孕周)、小于胎龄儿(<第10百分位)及其复合终点。

临床怎么用

  • 原文结论支持指南推荐妊娠期启动抗逆转录病毒治疗的女性使用以多替拉韦为基础的方案。
  • 作者认为需要采取干预措施以减轻产后体重增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated associations between antepartum weight change and adverse pregnancy outcomes and between antiretroviral therapy (ART) regimens and week 50 postpartum body mass index in IMPAACT 2010. METHODS: Women with human immunodeficiency virus (HIV)-1 in 9 countries were randomized 1:1:1 at 14-28 weeks' gestational age (GA) to start dolutegravir (DTG) + emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) versus DTG + FTC/tenofovir disoproxil fumarate (TDF) versus efavirenz (EFV)/FTC/TDF. Insufficient antepartum weight gain was defined using Institute of Medicine guidelines. Cox-proportional hazards regression models were used to evaluate the association between antepartum weight change and adverse pregnancy outcomes: stillbirth (≥20 weeks' GA), preterm delivery (<37 weeks' GA), small size for GA (<10th percentile), and a composite of these endpoints. RESULTS: A total of 643 participants were randomized: 217 to the DTG + FTC/TAF, 215 to the DTG + FTC/TDF, and 211 to the EFV/FTC/TDF arm. Baseline medians were as follows: GA, 21.9 weeks; HIV RNA, 903 copies/mL; and CD4 cell count, 466/μL. Insufficient weight gain was least frequent with DTG + FTC/TAF (15.0%) versus DTG + FTC/TDF (23.6%) and EFV/FTC/TDF (30.4%). Women in the DTG + FTC/TAF arm had the lowest rate of composite adverse pregnancy outcome. Low antepartum weight gain was associated with higher hazard of composite adverse pregnancy outcome (hazard ratio, 1.44 [95% confidence interval, 1.04-2.00]) and small size for GA (1.48 [.99-2.22]). More women in the DTG + FTC/TAF arm had a body mass index ≥25 (calculated as weight in kilograms divided by height in meters squared) at 50 weeks postpartum (54.7%) versus the DTG + FTC/TDF (45.2%) and EFV/FTC/TDF (34.2%) arms. CONCLUSIONS: Antepartum weight gain on DTG regimens was protective against adverse pregnancy outcomes typically associated with insufficient weight gain, supportive of guidelines recommending DTG-based ART for women starting ART during pregnancy. Interventions to mitigate postpartum weight gain are needed.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hoffman RM, Brummel S, Ziemba L, et al. Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum. Clin Infect Dis. 2024. PMID: 38180851. doi:10.1093/cid/ciae001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。